<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697668</url>
  </required_header>
  <id_info>
    <org_study_id>NUREX S.r.l</org_study_id>
    <nct_id>NCT03697668</nct_id>
  </id_info>
  <brief_title>Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites</brief_title>
  <acronym>Artesynib</acronym>
  <official_title>Triple Antimalarial Combination (Imatinib-DHA-PPQ) to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nurex S.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Università degli Studi di Sassari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Purdue University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vinmec Healthcare System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nurex S.r.l.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide a new drug combination for a better treatment of P.
      falciparum for a faster parasite clearance and to counteract artemisinin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to WHO, resistance to artemisinin derivatives (ART) is emerging in many areas of
      the Greater Mekong Region as a delayed parasite clearance following a standard treatment by
      artemisinin combined therapy (ACT). Artemisinin resistance is often accompanied by the
      resistance to the partner drugs such as piperaquine (PPQ), mefloquine (MEF), amodiaquine (AQ)
      and lumefantrine (LF).

      The slow and incomplete clearance of parasites following ACT treatment is considered to
      permit the selection of resistant parasites.

      The availability of new, more efficient treatments accelerating the clearance of parasites is
      therefore needed to counteract the selection of ART resistant strains.

      Imatinib (IMA) has been demonstrated to increase the efficacy of ART in a synergic fashion.
      This positive effect is further potentiated by low concentrations of PPQ.

      IMA is active both on the intra-erythrocyte asexual forms and on gametocytes. It is therefore
      expected that the combination DHA-PPQ-IMA should lead to faster and radical clearance of the
      parasites, therefore reducing the frequency of healthy carriers and transmission.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>interventional</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The research method will be a Phase 2 trial, 2 arms, randomized, open label (only the microscopist will be blinded), adaptive, dose de-escalation, trial conducted in adult male subjects with uncomplicated P.falciparum malaria.
In all phases, patients will be treated by a triple combination IMA-DHA-PPQ (ARM 1) or by the standard DHA-PPQ treatment (ARM 2).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>From baseline to day 42</time_frame>
    <description>Occurrence of Adverse Events over 42 days observation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Severe Adverse Events</measure>
    <time_frame>From baseline to day 42</time_frame>
    <description>Occurrence of Severe Adverse Events over 42 days observation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal Physical Symptoms</measure>
    <time_frame>From baseline to day 42</time_frame>
    <description>Occurrence of Abnormal Physical Symptoms (Clinical Abnormalities) over 42 days observation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal Laboratory Values</measure>
    <time_frame>From baseline to day 42</time_frame>
    <description>Occurrence of Abnormal Laboratory Values over 42 days observation period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of residual parasitemia: % of patients with &gt;1000 parasites/ ul at day 3 and 28</measure>
    <time_frame>day 3 and day 28</time_frame>
    <description>Parasitemia is determined by assessing the parasite count in blood, using thin film, thick film and qPCR analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of fever and malaria symptoms</measure>
    <time_frame>day 3 and day 28</time_frame>
    <description>Percentage of patients with fever or malaria symptoms observed at Phisical Visit at day 3 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean parasitemia in the control and investigational arms</measure>
    <time_frame>day 2 and day 5</time_frame>
    <description>Mean parasitemia by assessing the parasite count in blood, using thin film, thick film and qPCR analysis, expressed as parasites / ul at day 2, 3 and 5 measured in the control and investigational arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite half-life measured at 12 and 24 hours</measure>
    <time_frame>from baseline to 24 hours post-treatment</time_frame>
    <description>Mean parasite clearance half-life calculated using parasitemia measured at baseline, 12 and 24 hours post-treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Plasmodium Falciparum Malaria (Drug Resistant)</condition>
  <arm_group>
    <arm_group_label>imatinib-Dihydroartemisinin-piperaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>triple combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroartemisinin-piperaquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>triple combination for the treatment of malaria</description>
    <arm_group_label>imatinib-Dihydroartemisinin-piperaquine</arm_group_label>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-piperaquine</intervention_name>
    <description>standard malaria treatment</description>
    <arm_group_label>Dihydroartemisinin-piperaquine</arm_group_label>
    <other_name>Artekin</other_name>
    <other_name>Eurartesim</other_name>
    <other_name>Diphos</other_name>
    <other_name>Timequin</other_name>
    <other_name>Duocotecxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with mild to moderate P. falciparum malaria

          2. Adult male, age 18-55 years

          3. Good health conditions other than malaria

          4. The patient did not take anti-malarial drugs in the past 4 weeks

        Exclusion Criteria:

          1. unable to provide Informed Consent or Patient History Form

          2. symptoms and signs of severe or complicated malaria including: continuous high fever
             over 39 °C, confusion, convulsions

          3. parasitemia&lt;150.000 parasites /microliter

          4. other neurological or psychiatric symptoms or disorders

          5. abnormal bleeding

          6. resting hearth rate lower than 60 and higher than 100 bpm

          7. abnormal ECG, history of cardiac diseases

          8. male adults with corrected QT intervals &gt; 450ms

          9. signs, symptoms and laboratory results of impairment of vital organs such as liver,
             lungs, kidney and cardiovascular system

         10. hemoglobin &lt; 9.0 gm/100ml

         11. symptoms and signs of infection such as pneumonia, dengue fever, and other viral or
             bacterial infection.

         12. patients with symptoms of gastrointestinal infections or any sign of malabsorption
             that may interfere with drug absorption

         13. concomitant infection by plasmodium species other than P. falciparum

         14. inability to meet daily with local doctor during period of clinical trial

         15. concomitant medicines like:

               1. medicines used to treat high cholesterol in the blood (such as atorvastatin,
                  lovastatin, simvastatin);

               2. medicines used to treat hypertension and heart problems (such as diltiazem,
                  nifedipine, nitrendipine, verapamil, felodipine, amlodipine);

               3. medicined used to treat HIV (antiretroviral medicines): protease inhibitors (such
                  as amprenavir, atazanavir, indinavir, nelfinavir, ritonavir), non-nucleoside
                  reverse transcriptase inhibitors (such as efavirenz, nevirapine);

               4. medicines used to treat microbial infections (such as telithromycin, rifampicin,
                  dapsone);

               5. medicines used to help you fall asleep: benzodiazepines (such as midazolam,
                  triazolam, diazepam, alprazolam), zaleplon, zolpidem;

               6. medicines used to prevent/treat epileptic seizures: barbiturates (such as
                  phenobarbital), carbamazepine or phenytoin;

               7. medicines used after organ transplantation and in autoimmune diseases (such as
                  cyclosporin, tacrolimus);

               8. sex hormones, including those contained in hormonal contraceptives (such as
                  gestodene, progesterone, estradiol), testosterone; - glucocorticoids
                  (hydrocortisone, dexamethasone); - omeprazole (used to treat diseases related to
                  gastric acid production);

               9. paracetamol (used to treat pain and fever);

              10. theophylline (used to improve bronchial air flow);

              11. nefazodone (used to treat depression);

              12. aprepitant (used to treat nausea);
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huynh D Chien, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIVERSITY OF HUE, VIETNAM AND VINMEC DANANG INTERNATIONAL HOSPITAL, Hai Chau, Danang.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco M Turrini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huynh D Chien, MD,PhD</last_name>
    <phone>+84903580518</phone>
    <email>huynhdinhchien55@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tran A Tuan, MD</last_name>
    <phone>+84982290426</phone>
    <email>tuanhuonghoa@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A Tuc</name>
      <address>
        <city>Hương Hóa</city>
        <state>Quang Tri</state>
        <zip>520000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuan A Tran, MD</last_name>
      <phone>+84982290426</phone>
      <email>tuanhuonghoa@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Imatinib Mesylate</keyword>
  <keyword>piperaquine phosphate</keyword>
  <keyword>dihydroartemisinin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

